AKT1 and hepatocellular carcinoma: Studies have found that Nrf2 is activated by the PI3K/Akt pathway (9, 10), and abnormal activation of the PI3K/Akt pathway is also an important factor leading to resistance to sorafenib in HCC (11, 12).